Uplizna is a medicine used to treat adults with neuromyelitis optica spectrum disorders (NMOSD), inflammatory disorders that affect mainly the optic nerve (which connects the eye to the brain) and the spinal cord. This leads to impaired vision, loss of sensation, loss of bladder control, weakness and paralysis of the arms and legs. The medicine is used in patients with antibodies against a protein called aquaporin-4 (AQP4). Uplizna contains the active substance inebilizumab.
Therapeutic Indication
### Therapeutic indication Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
L04AA
ATC Item
选择性免疫抑制剂
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
EMA Name
Uplizna
Medicine Name
Uplizna
Aliases
N/A